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The Emerging Nosocomial Pathogens Cryptosporidium,
Escherichia coli O157:H7, Helicobacter pylori, and
Hepatitis C: Epidemiology, Environmental Survival,
Efficacy of Disinfection, and Control Measures
David J. Weber, MD, MPH; William A. Rutala, PhD, MPH
New and emerging infectious diseases pose a threat to pub-
lic health and may be responsible for nosocomial outbreaks.
Cryptosporidium parvum and Escherichia coli are gastrointestinal
pathogens that have caused nosocomial infections via person-to-
person transmission, environmental contamination, or contaminat-
ed water or food. Helicobacter pylori has been transmitted via inad-
equately disinfected endoscopes. Finally, hepatitis C may be
acquired by healthcare personnel by percutaneous or mucous
membrane exposure to blood or between patients by use of conta-
minated blood products or via environmental contamination.
Rigorous adherence to Standard Precautions, Contact Precautions
for patients with infectious diarrhea, disinfection of environmental
surfaces, and appropriate disinfection of endoscopes are adequate
to prevent nosocomial acquisition of these pathogens  (Infect
Control Hosp Epidemiol 2001;22:306-315).
The 1992 report by the Institute of Medicine,
“Emerging Infections: Microbial Threats to Health in the
United States,” called attention to the threats posed by
new and emerging infectious diseases.1 The multiple rea-
sons for the emergence of new infectious diseases or
increasing incidence of previously described agents have
been well described in review articles.2,3 Infection control
professionals must deal with new and emerging nosoco-
mial pathogens. The reasons for the emergence of new
nosocomial pathogens include enhanced survival of
immunocompromised hosts, acquisition and spread of
adaptive genes (ie, antibiotic resistance and virulence
genes), enhanced ability to survive in new ecologic nich-
es, increasing use of invasive procedures, unrecognized
virulence, prior under-identification due to difficulties in
culturing, and increased recognition due to taxonomic
clarification.4
This article will review the epidemiology, environ-
mental survival, efficacy of disinfection and sterilization,
and control measures of several emerging nosocomial
pathogens: Cryptosporidium parvum, Escherichia coli
O157:H7, Helicobacter pylori, and hepatitis C.
CRYPTOSPORIDIUM SPECIES
Epidemiology and Nosocomial Significance
C parvum, a protozoa belonging to the suborder
Eimeriina, is a well-recognized cause of gastroenteritis in
both immune-compromised5,6 and immune-competent per-
sons.7 Infection is acquired via ingestion of cryptosporidial
cysts and has been linked to potable water8; ingestion of
contaminated food9,10; drinking unpasteurized apple juice11;
recreational water activities, including swimming
pools,8,12,13 lakes,8 and water parks14; close person-to-person
contact7; and contact with farm animals.15
Cryptosporidiosis represents an important emerging
highly infectious pathogen for the following reasons.16-19
First, it is a common cause of self-limited gastroenteritis in
the normal host and can cause potentially life-threatening
disease in immunocompromised persons. Second, it is a
highly infectious enteric pathogen. Based on human volun-
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teer studies, the dose necessary to infect 50% of those
exposed (ID50) has been estimated at only 132 oocysts;
some infections followed the ingestion of only 30 oocysts,20
and infections after the ingestion of a single oocyst have
been reported.21 Third, it is persistent in water and resis-
tant to chlorine at levels used in potable and swimming-
pool water.22,23 Fourth, it is ubiquitous in many feral,
domestic, and agricultural animals, representing a major
threat to the water supply in the United States. The small
dose required for infection, the fecal-oral route of transmis-
sion, and prolonged environmental survival in water allows
Cryptosporidium to spread in households, healthcare facili-
ties, and child-care centers.
Nosocomial transmission has been reported.24-30
Direct24,25 and indirect26-28 person-to-person transmission
(via contaminated hands) has been incriminated as the like-
ly mechanism of transmission. In addition, ice contaminat-
ed by a patient has led to an outbreak among patients and
staff.29 Multiple outbreaks have been reported in child-care
centers.31-34 Outbreaks in veterinary facilities have involved
students and staff.35
Cryptosporidium poses significant challenges to pub-
lic health and water authorities.36 Large outbreaks of cryp-
tosporidiosis associated with contaminated drinking water
have occurred in Milwaukee37 and Las Vegas.38 Overall,
cryptosporidiosis accounted for more than 70% of illnesses
associated with drinking water outbreaks reported to the
Centers for Disease Control and Prevention (CDC)
between 1997 and 1998.8
Environmental Survival
C parvum is capable of surviving for long periods of
time when immersed in water. First-order kinetics of die-off
rates of C parvum experimentally exposed to natural river
water ranged from 0.013 to 0.039 log10 per day.
39 Die-off was
higher in natural river water than in synthetic hard water.39
The survival of C parvum on experimentally
contaminated environmental surfaces has been exam-
ined. Robertson et al used a vital dye test to evaluate C
parvum oocyst survival on surfaces at room temperature
and observed 97% loss of viability by 2 hours and 100% by
4 hours.40 Barbee and colleagues, using a viability assay,
reported the following decreases in infective C parvum
oocysts with time: 30 minutes, 2.9-log10; 60 minutes, 3.8-
log10; and 90 minutes, >4.0-log10.
41 More prolonged sur-
vival has been reported when Cryptosporidium in a diar-
rheal stool is applied to an environmental surface;
Anderson noted that Cryptosporidium in a diarrheal stool
smeared on a wooden surface survived for up to 72
hours.42 
Efficacy of Disinfection and Sterilization
Cryptosporidium is relatively resistant to chlorine at
concentrations used in potable water. C parvum is not com-
pletely inactivated by most disinfectants used in health
care, including ethyl alcohol,41 glutaraldehyde,41,43 5.25%
hypochlorite,41 peracetic acid,41 ortho-phthalaldehyde,41
phenol,41,43 povidone-iodine,41-43 and quaternary ammoni-
um compounds41 (Table 1). The only chemical disinfec-
tants or sterilants able to inactivate greater than 3 log10 of C
parvum were 6% and 7% hydrogen peroxide.41 Sterilization
methods that will fully inactivate C parvum include steam,41
ethylene oxide,41,44 and the Sterrad 100.41
Control Measures
The major threat posed by Cryptosporidium in the
hospital is the acquisition of infection by immunocompro-
mised patients via ingestion of contaminated potable water.
The CDC has recommended that human immunodeficiency
virus (HIV)-infected persons who wish to take independent
action to reduce risk for waterborne cryptosporidiosis may
choose to take precautions similar to those recommended
during outbreaks (ie, ingest water that has been boiled for 1
minute or filtered through a submicron filter).45 Recently
the CDC recommended that hematopoietic stem cell trans-
plant (HSCT) recipients should avoid the following activities
to prevent exposure to Cryptosporidium: walking, wading,
swimming, or playing in recreational water likely to be con-
taminated with Cryptosporidium, sewage, or animal or
human wastes; ingesting water taken directly from rivers
and lakes; and use of water from private wells or public wells
in communities with limited populations.46 To eliminate the
risk of Cryptosporidium from tap water completely, HSCT
recipients can either boil or filter the water. Similar recom-
mendations have been published in England.47 It would be
prudent for hospitals to provide all immunocompromised
persons (eg, due to chemotherapy or being IgA deficient or
HIV-infected) with sterile water and ice for ingestion.
Patients with cryptosporidiosis can be managed
using Standard Precautions.48 This CDC recommendation
recently was validated by a retrospective cohort study of 37
TABLE 1
EFFICACY OF DISINFECTION METHODS AGAINST CRYPTOSPORIDIUM
PARVUM
Ineffective Methods
Quaternary ammonium (use dilution, 20°C, 10 min)
Hypochlorite (5.25%, 20°C, 10 min)
Phenolic (use dilution, 20°C, 10 min)
Iodophor (1%, 20°C, 20 min) 
Ethyl alcohol (70%, 20°C, 20 min) 
Hydrogen peroxide (3%, 20°C, 10 min)
Hydrogen peroxide (3%, 20°C, 20 min)
Hydrogen peroxide (6%, 20°C, 10 min)
Glutaraldehyde (2.4%, 25°C, 45 min)
Peracetic acid (0.35%, 20°C, 20 min)
Peracetic acid (0.2%, 50°C, 12 min)
Peracetic acid (0.2%, 23-25°C, 12 min)
Ortho-phthalaldehyde (undiluted, 20°C, 20 min)
Effective Methods
Hydrogen peroxide (6%, 20°C, 20 min)*
Hydrogen peroxide (7.5%, 20°C, 20 min)*
* >3-log kill.
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hospitalized patients, which failed to identify roommate-to-
roommate transmission of Cryptosporidium.49 Contact
Precautions should be used for diapered or incontinent
children less than 6 years of age for the duration of the ill-
ness. HIV-infected patients, especially those who are
severely immunocompromised, should not share a room
with persons infected with Cryptosporidium.45
Current hospital cleaning practices appear satisfacto-
ry to prevent nosocomial transmission. Chest-type ice
machines should not be used in clinical areas of the hospi-
tal to prevent possible contamination.29 Endoscopes are
unlikely to represent an important vehicle for the cross-
transmission of C parvum, because mechanical cleaning
will remove approximately 104 organisms, and rapid drying
results in loss of C parvum viability.41
ESCHERICHIA COLI O157:H7
Epidemiology and Nosocomial Significance
There has been growing appreciation of the major
public health impact of foodborne diseases50-53 and the
importance of E coli O157:H7 as a foodborne
pathogen.54,55 E coli O157:H7 was first recognized as a
human pathogen in 1982, when two outbreaks in the
United States were associated with eating undercooked
hamburgers.56,57 Currently, E coli O157:H7 is estimated to
result annually in 20,000 cases of gastroenteritis and 100
to 200 deaths.51 E coli O157:H7 is transmitted from its
bovine reservoir to humans via direct contact or via cont-
aminated water or food.58 Raw or undercooked meat has
been the food item most commonly associated with out-
breaks of E coli O157:H7, but infection has followed inges-
tion of other contaminated foods, including vegetables
such as lettuce and radish sprouts; unpasteurized juice,
milk, or cheese; and water.59,60 Secondary person-to-
person transmission may occur following initial human
infection; the household transmission rate has been cal-
culated to be 4% to 15%.61 Person-to-person transmission is
facilitated by the low inoculum dose required for infec-
tion. In two outbreak investigations, the infectious dose of
E coli O157:H7 was found to be fewer than 700 organ-
isms62 and fewer than 50 organisms.63
Nosocomial outbreaks of E coli O157:H7 have been
reported occasionally.64-68 Evaluations of these outbreaks
have suggested direct person-to-person transmission,65-68
indirect transmission via environmental contamination,68
and contaminated food (lettuce).66 Transmission from
patients to staff has been reported, but the number of staff
infected in such incidents usually is low.67,68 Outbreaks also
have been reported in child-care centers69-71 and extended-
care facilities.72,73 In some reported outbreaks, it has not
been possible to establish if staff have acquired infection
from eating the same implicated food or secondarily from
patients.66-73
Environmental Survival
E coli O157:H7 is capable of surviving for prolonged
periods of time in soil, meats, and produce. For example,
E coli O157:H7 was capable of surviving for up to 144
hours in untreated milk held at 7°C without a change in
colony counts, but when held at 15°C a 3.7-log10 increase
was noted.74 When inoculated into chicken manure, E coli
O157:H7 demonstrated a 1- to 2-log10 increase over a peri-
od of 2 days at 20°C.75 Drying of the manure to 10% mois-
ture at 20°C resulted in 1- to 2-log10 decrease in counts
over 24 hours. When inoculated onto lettuce, E coli
O157:H7 was demonstrated to survive at 4°C for up to 15
days.76
Efficacy of Disinfection and Sterilization
Disinfectants, including chlorine compounds, are
unable to eliminate E coli O157:H7 experimentally inocu-
lated onto alfalfa seeds or sprouts77,78 or beef-carcass sur-
faces.79 However, chlorine at approximately 1 ppm has
been found capable of eliminating approximately 4 log10
of E coli O157:H7 within 1 minute in a suspension test.80
Electrolyzed oxidizing water at 23°C was effective
in 10 minutes in producing a 5-log10 decrease in E coli
O157:H7 inoculated onto kitchen cutting boards.81 The
following disinfectants were effective in eliminating >5
log10 of E coli O157:H7 within 30 seconds: a quaternary
ammonium compound, a phenolic, a hypochlorite (1:10
dilution of 5.25% bleach), and ethanol82 (Table 2).
Control Measures
E coli represents an important public health threat.
Consumers are advised to follow food-safety guidelines.83
These include thorough heating of potentially hazardous
foods and prompt refrigeration of used foods. Additional
measures include separating cooked and raw foods and
preventing contamination of cooked foods by drippings
from raw foods. Contaminated surfaces (eg, cutting
boards) should be washed. Consumers should consider
avoiding high-risk foods such as raw or runny eggs and
undercooked hamburger meat (ie, pink or red in center).
Raw sprouts should not be consumed by the elderly, chil-
dren, and those with a compromised immune system.84
Patients infected with E coli O157:H7 can be man-
aged using Standard Precautions.48 Contact Precautions
should be used for diapered or incontinent children less
than 6 years of age for the duration of the illness.
Standard hospital surface disinfectants are adequate for
inactivating E coli O157:H7 and can be used for terminal
cleaning or cleaning of contaminated surfaces. Current
TABLE 2
EFFICACY OF DISINFECTION METHODS AGAINST ESCHERICHIA COLI
O157:H7
Effective Methods
Quaternary ammonium (use dilution, 20°C, 0.5 min)*
Hypochlorite (0.525%, 20°C, 0.5 min)*
Phenolic (use dilution, 20°C, 0.5 min)*
Ethyl alcohol (70%, 20°C,  0.5 min)*
*> 5-log kill.
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guidelines for the disinfection of endoscopes should be
followed. 
HELICOBACTER PYLORI
Epidemiology and Nosocomial Significance
H pylori is a fastidious, microaerophilic, spiral-
shaped, gram-negative rod. First isolated in 1983,85,86 H
pylori is now known to play an important role in the devel-
opment of gastritis, peptic ulcer disease, distal gastric ade-
nocarcinoma, and gastric lymphoma.87-89 The incidence of
H pylori infection in developed countries has been estimat-
ed to be approximately 0.5%, with the incidence decreasing
over time.90
The route of H pylori transmission remains a topic
of intense controversy because of incomplete informa-
tion, including how the organism leaves its host and
enters the environment, where (if anywhere) the organ-
ism persists in the environment, how people become
infected, and whether all persons are susceptible to infec-
tion.88,91 Circumstantial evidence suggests that the most
likely means of H pylori transmission is direct person-to-
person spread. This may occur via fecal-oral, oral-oral, or
gastric-oral routes. Fecal-oral transmission is suggested
by the finding of higher prevalence rates of infection in
crowded households, institutions for the disabled, or
households with young children.88 Fecal-oral transmis-
sion is supported by the occasional isolation of H pylori
from the stools of adults92,93 and children.92 Oral-oral
transmission is suggested by the ability to detect H pylori
DNA by polymerase chain reaction (PCR) from both sali-
va and dental plaque, although viable H pylori have only
occasionally been isolated from the mouth.94 Gastric-oral
transmission has been suggested by iatrogenic transmis-
sion of H pylori in endoscopy suites (see below).
Epidemiological studies of Peruvian children have shown
that H pylori infection is associated with consuming food
from street vendors95 and drinking potable water from
community wells,96 thus suggesting transmission via con-
taminated food and water. 
Nosocomial transmission of H pylori via inade-
quately cleaned and disinfected medical equipment, most
commonly endoscopes, has been suggested by epidemio-
logical investigations and demonstrated by molecular
techniques.97 H pylori has been isolated from used endo-
scopes and biopsy forceps.98 Epidemic gastritis with
hypochlorhydria, a syndrome compatible with H pylori
infection, has been reported following the use on multiple
patients of pH electrodes that were not disinfected
between patients.99,100 Epidemiological investigations
have suggested cross-transmission of H pylori by poten-
tially contaminated endoscopes.101-103 Patient-to-patient
transmission of H pylori via contaminated endoscopes has
been proven by use of molecular techniques104,105; all
cases of transmission have followed the use of ineffective
disinfectants such as 70% ethanol103,104 or 0.2% benzethonium
chloride.101
Mouth-to-mouth transmission has been reported to
lead to acquisition of H pylori.106 A sero-epidemiological
study demonstrated that endoscopy personnel had a high-
er prevalence of H pylori than blood donors, raising the
potential that H pylori was an occupational hazard.107
However, the use of a highly screened population (ie, blood
donors) as a control group may have been inappropriate.
Further, seropositivity was not associated with years
involved in endoscopy or number of endoscopies per-
formed monthly. 
Environmental Survival
Data on the environmental survival of H pylori is
limited. H pylori can change from its normal rod-like
appearance into a range of coccoidal forms, especially
after antibiotic treatment or in vitro after prolonged cul-
ture. In the coccoidal form, H pylori cannot be grown in cul-
ture, and thus it is believed that the hypothesis that H pylori
is a zoonosis or transmitted as coccoid forms by vectors
(pets, houseflies) is not supported by recent research.108 It
also is unknown whether the coccoidal forms can revert to
the spiral, multiplying forms. However, Cellini and col-
leagues demonstrated in a rodent model that administra-
tion of the coccoid form of H pylori resulted in infection.109
The viability of the coccoidal forms represents an impor-
tant scientific question bearing on the potential infectivity
of contaminated water and food, and the role of the envi-
ronment in transmission of H pylori.
In an early experiment, the median survival of H
pylori in distilled water or saline was found to be only 0 to 2
days.110 Using a higher titer of H pylori, Shahamat demon-
strated that H pylori could survive for 48 hours in sterile
river water at 4°C; in some cases, viable bacteria were cul-
turable for up to 20 to 30 days, depending on physical con-
ditions of the environment.111 H pylori is capable of surviv-
ing for up to 10 days in milk at 4°C and 4 days in tap water,
with a steady decrease in colony-forming units; the non-
culturable coccoid form was present at 7 days in tap water
kept at 4°C.112 H pylori DNA has been detected by PCR in
12% to 36% of potable-water sites (private wells, municipal
tap water, wastewater) tested in Sweden113 and in samples
of tap water, well water, and field soil in Japan.114
The survival of H pylori on environmental surfaces
has not been determined. 
Efficacy of Disinfection and Sterilization
Only limited data are available on the susceptibility
of H pylori to disinfectants (Table 3). Using a suspension
TABLE 3
EFFICACY OF DISINFECTION METHODS AGAINST HELICOBACTER
PYLORI
Effective Methods
Hypochlorite (150 ppm, 25°C, 0.5 min)*
Ethyl alcohol (80%, 25°C, 0.25 min)*
Glutaraldehyde (0.5%, 25°C, 0.25 min)*
* >7-log kill.
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test, Akamatsu and colleagues assessed the effectiveness
of a variety of disinfectants against nine strains of H
pylori.115 Ethanol (80%) and glutaraldehyde (0.5%) killed
all strains within 15 seconds, whereas chlorhexidine glu-
conate (0.05% and 1.0%), benzalkonium chloride (0.025%
and 0.1%), alkyldiaminoethylglycine hydrochloride
(0.1%), povidone-iodine (0.1%), and sodium hypochlorite
(150 ppm) killed all strains within 30 seconds. Both
ethanol (80%) and glutaraldehyde (0.5%) retained similar
bactericidal activity in the presence of organic matter,
whereas the other disinfectants showed reduced bacteri-
cidal activity. In particular, the bactericidal activities of
povidone-iodine (0.1%) and sodium hypochlorite (150
ppm) were markedly decreased in the presence of dried
yeast solution, with killing times increased to 5 to 10 min-
utes and 5 to 30 minutes, respectively.
Immersion of biopsy forceps in formalin prior to
obtaining a specimen does not affect the ability to obtain
a culture of H pylori from the biopsy specimen.116 The fol-
lowing methods have been demonstrated to be ineffec-
tive for eliminating H pylori from endoscopes: cleaning
with soap and water,117,118 immersion in 70% ethanol for 3
minutes,104 instillation of 70% ethanol,103 instillation of 30
mL of 83% methanol,117 and 0.2% benzethonium chloride
solution.101 The differing results with regard to the effi-
cacy of ethyl alcohol are unexplained. Cleaning followed
by use of 2% alkaline glutaraldehyde has been demon-
strated by culture to be effective in eliminating H
pylori.117-119 Epidemiological investigations of patients
who had undergone endoscopy with scopes mechanically
washed and disinfected with 2.0% to 2.3% glutaraldehyde
have revealed no evidence of cross-transmission of H
pylori.103-120 Disinfection of experimentally contaminated
endoscopes using 2% glutaraldehyde (10-m, 20-m, and 45-
m exposure times) or the Steris (Steris Corp, Menton,
OH) system (with and without active peracetic acid) has
been demonstrated to be effective in eliminating H
pylori.118 H pylori DNA has been detected by PCR in fluid
flushed from endoscope channels following cleaning and
disinfection with 2% glutaraldehyde.121 The clinical signif-
icance of this finding is unclear. 
In vitro experiments have demonstrated a >3.5-log10
reduction in H pylori after exposure to 0.5 mg/L of free
chlorine for 80 seconds.122
Control Measures
H pylori represents an important nosocomial
pathogen that commonly contaminates endoscopes and
has been transmitted by inadequately cleaned and disin-
fected scopes. However, cleaning followed by disinfection
of endoscopes with 2.0% glutaraldehyde or peracetic
acid has been demonstrated to be effective in eliminating
H pylori. Standard chlorination of potable water appears
adequate to eliminate the possibility of transmission via
contaminated water. Studies demonstrating an increased
risk of H pylori among endoscopic personnel are flawed,
and additional studies should be undertaken before con-
cluding that such personnel are at increased risk for
acquisition of H pylori. However, personnel should use
Standard Precautions when performing endoscopy.
Although data are lacking regarding the possibility of
person-to-person transmission when close contact occurs,
the possibility of transmission cannot be ruled out in set-
tings such as child-care centers and institutions caring for
mentally disabled children. 
HEPATITIS C
Epidemiology and Nosocomial Significance
Hepatitis C (HCV), an RNA virus, is the most com-
mon chronic bloodborne infection in the United States.
The annual number of new infections in 1996 was 36,000,
which represents a decline of more than 80% since
1989.123 Data from the Third National Health and
Nutrition Examination Survey, conducted from 1988
through 1994, indicated that an estimated 1.8% of US res-
idents have been infected with HCV.124 The estimated
prevalence in selected population groups is as fol-
lows123,125: persons with hemophilia treated with product
made before 1987, 87%; current injecting drug users, 79%;
chronic hemodialysis patients, 10%; persons reporting a
history of sexually transmitted diseases, 6%; infants born
to infected mothers, 5%; men who have sex with other
men, 4%; and volunteer blood donors, 0.16%. Population-
based studies indicate that 40% of chronic liver disease is
HCV-related, resulting in an estimated 8,000-10,000
deaths per year.123
HCV is transmitted primarily through large or
repeated direct percutaneous exposures to blood. The
majority of patients infected with HCV in the United States
and Europe acquired the disease through transfusion or
injecting drug use. Prior to the discovery of HCV in 1989
and the subsequent implementation of an HCV-antibody
detection assay for screening of blood donors in 1990, the
risk of acquiring HCV through blood transfusion was as
high as 1 in 200 units.126 Following the introduction of
improved HCV antibody assays in 1992 and 1996, the risk
fell to 1 per 103,000 units of blood.127 With the introduction
of nucleic acid testing in the spring of 1999, it is estimated
that the risk of transfusion-transmitted HCV will fall to
between 1 in 500,000 and 1 in 1,000,000 units.126 HCV trans-
mission also was associated with use of tainted clotting-
factor concentrates in hemophiliacs,128 contaminated
immunoglobulin preparations used to treat patients with
humoral defects,129-131 contaminated anti-rhesus D prepara-
tions used in young women,132,133 and plasmapheresis.134,135
Transmission of HCV by infected donor tissue has been
demonstrated in kidney, heart, and liver transplantation.136
In the United States, no association has been found
between hepatitis C infection and exposures resulting from
medical, surgical, or dental procedures; tattooing, acupunc-
ture, or ear piercing; or foreign travel.125
Between 1983/84 and 1995/96, injecting drug use
became an increasingly important mechanism of HCV
acquisition, accounting for more than 50% of HCV trans-
mission in the United States. However, in parallel with
the overall decrease in HCV prevalence, the number of
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cases of acute HCV among injecting drug users has
declined dramatically since 1989. Currently, injecting
drug use accounts for 60% of HCV transmission, sexual
contact for 20%, and other known exposures (household,
perinatal, occupational) for 10%.125 In the remaining 10%,
no recognized source of infection can be identified,
although most persons in the category are associated
with low socioeconomic level. 
Nosocomial transmission of HCV has been
reviewed.123,137-140 The most important nosocomial source
was transfusions of blood products, until the development
and implementation of improved screening methods.
Hemodialysis patients are at high risk for acquisition of
hepatitis C. The prevalence of anti-HCV among dialysis
patients ranges from 8% to 36% in the United States141 and
from 1% to 47% worldwide.142,143 A survey of 2,647 US
hemodialysis centers in 1995 by the CDC revealed that the
prevalence of anti-HCV was 10.4% among patients.144 A
similar survey of 3,077 centers in 1997 revealed that the
prevalence of anti-HCV was 9.3% among the 48% of centers
that tested patients for anti-HCV.145 Patient-to-patient
transmission in hemodialysis centers has been confirmed
by molecular analysis of HCV strains isolated.146-152 Studies
have consistently demonstrated an association between
anti-HCV positivity and increasing years on dialysis, an
association that is independent of blood transfusions.140
Investigation of dialysis-associated outbreaks of hepatitis C
indicates that HCV transmission might occur among
patients in a hemodialysis center because of incorrect
implementation of infection control practices, especially
sharing medication vials and supplies.123 HCV has been
detected by PCR on the hands of healthcare personnel car-
ing for hemodialysis patients, despite the use of Standard
Precautions.153
Nosocomial transmission of HCV has only occasion-
ally been reported in healthcare settings other than
hemodialysis. HCV has been transmitted at least twice dur-
ing colonoscopy.154,155 The former case was likely due to
inadequate cleaning and disinfection of the colonoscope,
whereas the latter case was likely due to use of a multidose
anesthetic vial or a shared syringe. In addition, HCV has
been transmitted during endoscopic retrograde cholan-
giography.156 An outbreak on a pediatric oncology ward was
felt to be due to contamination of multidose vials.157 An
investigation of institutionalized psychiatric patients
revealed a higher-than-expected prevalence of anti-HCV.158
A case-control study demonstrated the following indepen-
dent risk factors for infection: duration of hospitalization,
age, razor sharing, and history of surgery. On this basis, the
authors suggested that razor sharing be avoided.158 An out-
break of hepatitis C infection confirmed by molecular typing
was reported in a fertility clinic during procedures for
assisted conception.159 Despite an extensive investigation,
the exact means of cross-transmission was not discovered,
and the most likely route of contamination was healthcare
workers. Schvarcz and colleagues160 investigated a cluster
of hepatitis C confirmed by phylogenetic analysis among
subjects participating in a research project; cross-
transmission was felt to result from the failure to adhere
strictly to Standard Precautions. Cross-transmission due to
contamination of anesthetic circuitry was suggested as the
cause of an outbreak of hepatitis C among patients who
had undergone surgery in the same operating suite on the
same day.161 This outbreak led to changes in local guide-
lines for infection control in anesthesiology162 and gener-
ated significant controversy about the potential mode of
cross-transmission,163,164 as well as the need to revise cur-
rent US infection control guidelines in anesthesiology.163.164
Lloyd and coworkers subsequently demonstrated that a
hydrophobic pleated-membrane breathing circuit filter con-
sistently prevented the passage of hepatitis C virus, where-
as a large-pore “electret” filter design was ineffective.165
Healthcare workers who frequently have contact
with blood are at risk of occupationally acquired infection
with bloodborne pathogens. However, the prevalence of
HCV infection among healthcare workers is approxi-
mately 1% to 2%.145,166-170 This rate, which includes ortho-
pedic, general, and oral surgeons, and hemodialysis staff,
is similar to the rate in the general population. Following
a percutaneous injury with a contaminated sharp or a
needlestick, the rate of seroconversion among healthcare
workers has averaged 1.8% (range, 0% to 7%).123 One
study from Japan, which used reverse transcriptase PCR
to detect HCV RNA, reported a seroconversion rate of
10% following contaminated needlestick injuries.171
Transmission of HCV has followed from blood splashed
to conjunctivae.172,173 No case reports have described
HCV transmission following blood exposure of nonintact
skin.
Physician-to-patient transmission of HCV has rarely
been reported, but three papers reported transmission dur-
ing surgery.174-176 In two reports only a single patient was
infected, but in one report five patients were infected175;
molecular typing suggested transmission from the health-
care worker.175,176
Environmental Survival
The environmental survival of HCV is unknown. No
studies have been conducted for HCV comparable to that
conducted by Favero and Bond,177 which demonstrated
that hepatitis B virus remains infectious for at least 1 week
on environmental surfaces. As measured by PCR, there is
a rapid decline in detectable HCV RNA of 3 to 4 log10 with-
in 14 days when HCV-contaminated whole blood and
serum were stored at room temperature.178
Efficacy of Disinfection and Sterilization 
Using experimentally contaminated hysteroscopes,
Sartor and colleagues detected HCV by PCR in 1 (3%) of
34 samples following cleaning with a detergent, but in no
samples following treatment with a 2% glutaraldehyde
solution for 20 minutes.179 Rey and colleagues demon-
strated complete elimination of hepatitis C virus by PCR
from endoscopes used on chronically infected patients fol-
lowing cleaning and disinfection for 3 to 5 minutes in glu-
taraldehyde.180 Similarly, Chanzy and coworkers used
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PCR to demonstrate complete elimination of HCV follow-
ing standard disinfection by experimentally contaminated
endoscopes.181
Control Measures
Transfusions now represent only a minimal risk for
the transmission of HCV in healthcare facilities.
Nosocomial transmission of HCV is possible if infection
control techniques or disinfection procedures are inade-
quate and contaminated equipment is shared among
patients.123 Fortunately, cases of nosocomial transmission
have been reported only rarely from the United States.
Standard methods of cleaning and disinfection appear ade-
quate to prevent transmission of HCV via contaminated
endoscopes.182 Additional studies to assess the mecha-
nisms of HCV transmission in hemodialysis centers are
needed. In addition, strategies to prevent transmission in
hemodialysis centers need to be validated.
HCV acquisition via percutaneous injury is an
important hazard for medical personnel. The lack of
proven effective pre- or postexposure prophylaxis, the
current prevalence of chronic HCV infection in the gener-
al (approximately 2%) and patient populations, and the
rate of seroconversion following percutaneous injuries
(1.8%) mean that HCV infection represents the most
important bloodborne-transmitted disease threat to
healthcare personnel. Efforts at prevention of HCV trans-
mission to healthcare workers should focus on general
measures to reduce the incidence of needlestick injuries. 
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